You are here: Industry Insights > boehringer

News List

Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment pharmatimes
November 19, 2018
German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, small molecule
GSK grabs new drug development head from Boehringer expressbpd
September 21, 2018
GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said recently.
Boehringer buys ViraTherapeutics pharmatimes
September 18, 2018
Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics.
Boehringer Provides CMC Services for CANbridge contractpharma
August 28, 2018
Beijing-based CANbridge Life Sciences has received clinical trial application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with its drug candidate CAN017.
Boehringer forms new alliance to develop gene therapy pharmaceutical-technology
August 08, 2018
Boehringer Ingelheim has entered a global partnership with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), Imperial Innovations and Oxford BioMedica (OXB) to develop a new long-term gene therapy for cystic fibrosis (CF).
Boehringer joins consortium to develop new cystic fibrosis gene therapies pharmatimes
August 07, 2018
Boehringer Ingelheim has partnered with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis
Boehringer sales rise as Jardiance and Ofev thrive pharmatimes
August 02, 2018
Boehringer Ingelheim saw its first-half prescription drug sales rise on the back of strong performances for Jardiance and Ofev.
Boehringer expands drug manufacturing capabilities in China pharmaceutical-technology
July 12, 2018
Boehringer Ingelheim has added a new filling line to its Oasis facility in Shanghai, China in order to expand and consolidate its contract drug manufacturing capabilities.
Boehringer Ingelheim Bolsters Biologics R&D contractpharma
July 03, 2018
Boehringer Ingelheim has unveiled plans to invest €230 million into a new Biologicals Development Center (BDC) at the company's research and development site in Biberach, Germany during the foundation stone laying for the new center.
Boehringer to invest €230m in biologics R&D pharmaceutical-technology
June 28, 2018
Boehringer Ingelheim has revealed plans to invest €230m into a new Biologicals Development Center (BDC) set to be constructed at its Research and Development (R&D) site located in Biberach, Germany.

Previous page 1 2 3 4 5 6 Next page